China's Jacobio hits 9-week peak on submission of new drug application

Jacobio Pharmaceuticals

07/05/2024 04:28

** Shares of new drug developer Jacobio Pharmaceuticals
Group Co Ltd  1167.HK  jump 35.5% to HK$2.52, their highest
since March 4
    ** Stock on course for the biggest one-day rise since debut
in December 2020; fifth biggest gainer on the Hong Kong bourse
    ** Jacobio says new drug application for its KRAS G12C
inhibitor Glecirasib (JAB-21822) has been submitted to the
Center for Drug Evaluation of China's National Medical Products
Administration (NMPA) for treatment of lung cancer
    ** Hong Kong's healthcare index  .HSCIH  slips 0.8%, Hang
Seng Composite Index  .HSCI  eases 0.5% and Hang Seng Index
 .HSI  declines 0.7x%
    ** Stock down 37.3% YTD  

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))